EMA Poses Three Questions For the Public Ahead Of Valproate Hearing
Executive Summary
The European Medicines Agency will be choosing speakers for its public hearing on valproate in September based on how they propose to address three questions. Pharmaceutical companies can apply too.
You may also be interested in...
Parties Vie For Place At EMA’s First Ever Public Hearing On Medicines Safety
The first ever public hearing on the safety of marketed medicines being organized by the European Medicines Agency has drawn a “very positive” response from the members of the public who have applied to attend the event on Sept. 26. The agency is now shortlisting an appropriate mix of speakers and observers.
EMA to go extra mile to facilitate joint safety study for valproate
In the course of its mandate to help companies carry out joint post-authorization safety studies under the EU pharmacovigilance legislation, the European Medicines Agency is planning to organize a teleconference/webinar for a new study concerning the anti-epileptic drug valproate so that interested companies may be introduced to each other and have the opportunity to interact and raise questions.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.